 Kennon Heard
Concepts (647)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acetaminophen | 41 | 2025 | 266 | 8.240 |
Why?
| | Chemical and Drug Induced Liver Injury | 16 | 2023 | 138 | 4.630 |
Why?
| | Analgesics, Non-Narcotic | 22 | 2025 | 127 | 4.490 |
Why?
| | Drug Overdose | 32 | 2025 | 374 | 3.930 |
Why?
| | Poison Control Centers | 13 | 2025 | 84 | 3.370 |
Why?
| | Emergency Service, Hospital | 41 | 2023 | 2377 | 3.010 |
Why?
| | Poisoning | 17 | 2017 | 119 | 2.830 |
Why?
| | Acetylcysteine | 12 | 2023 | 139 | 2.500 |
Why?
| | Alanine Transaminase | 14 | 2023 | 151 | 2.460 |
Why?
| | Cocaine | 10 | 2011 | 161 | 2.310 |
Why?
| | Cannabis | 9 | 2020 | 509 | 2.210 |
Why?
| | Prescription Drugs | 9 | 2018 | 110 | 2.110 |
Why?
| | Antidotes | 10 | 2023 | 145 | 1.600 |
Why?
| | Legislation, Drug | 5 | 2017 | 73 | 1.410 |
Why?
| | Analgesics, Opioid | 8 | 2023 | 1145 | 1.390 |
Why?
| | Cysteine | 4 | 2017 | 210 | 1.280 |
Why?
| | Antipsychotic Agents | 7 | 2019 | 211 | 1.250 |
Why?
| | Marijuana Use | 4 | 2021 | 221 | 1.120 |
Why?
| | Medication Errors | 5 | 2015 | 84 | 1.110 |
Why?
| | Pain | 9 | 2020 | 781 | 1.030 |
Why?
| | Male | 103 | 2022 | 72664 | 1.020 |
Why?
| | Cocaine-Related Disorders | 5 | 2011 | 133 | 1.020 |
Why?
| | Humans | 156 | 2025 | 145140 | 1.010 |
Why?
| | Drug Packaging | 2 | 2017 | 41 | 1.000 |
Why?
| | Emergency Medicine | 6 | 2019 | 282 | 1.000 |
Why?
| | Toxicology | 4 | 2021 | 49 | 1.000 |
Why?
| | Medication Reconciliation | 2 | 2016 | 32 | 0.910 |
Why?
| | Dose-Response Relationship, Drug | 16 | 2017 | 2026 | 0.890 |
Why?
| | Female | 96 | 2023 | 78636 | 0.890 |
Why?
| | Adult | 73 | 2022 | 40665 | 0.870 |
Why?
| | Antidepressive Agents, Tricyclic | 5 | 2014 | 31 | 0.840 |
Why?
| | Spider Bites | 5 | 2019 | 7 | 0.840 |
Why?
| | Antivenins | 5 | 2019 | 29 | 0.840 |
Why?
| | Diphenhydramine | 4 | 2023 | 36 | 0.830 |
Why?
| | Akathisia, Drug-Induced | 2 | 2020 | 5 | 0.810 |
Why?
| | Thiazoles | 4 | 2009 | 140 | 0.780 |
Why?
| | Prescription Drug Monitoring Programs | 1 | 2023 | 17 | 0.780 |
Why?
| | Spider Venoms | 4 | 2019 | 11 | 0.780 |
Why?
| | Benzodiazepines | 6 | 2023 | 168 | 0.770 |
Why?
| | Muscarinic Antagonists | 3 | 2023 | 30 | 0.750 |
Why?
| | Lorazepam | 3 | 2023 | 25 | 0.740 |
Why?
| | Heart Arrest | 8 | 2018 | 408 | 0.730 |
Why?
| | Young Adult | 30 | 2020 | 14176 | 0.710 |
Why?
| | Physostigmine | 2 | 2020 | 13 | 0.700 |
Why?
| | Middle Aged | 54 | 2022 | 36126 | 0.700 |
Why?
| | Emergency Treatment | 4 | 2015 | 123 | 0.690 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2019 | 343 | 0.690 |
Why?
| | Black Widow Spider | 4 | 2019 | 7 | 0.690 |
Why?
| | Piperazines | 4 | 2009 | 375 | 0.680 |
Why?
| | Medical History Taking | 3 | 2018 | 117 | 0.680 |
Why?
| | Dopamine Uptake Inhibitors | 3 | 2011 | 59 | 0.680 |
Why?
| | Decision Support Systems, Clinical | 2 | 2023 | 271 | 0.670 |
Why?
| | Seizures | 6 | 2011 | 482 | 0.670 |
Why?
| | Referral and Consultation | 2 | 2020 | 862 | 0.670 |
Why?
| | Delirium | 2 | 2020 | 105 | 0.660 |
Why?
| | Abdominal Pain | 2 | 2019 | 149 | 0.640 |
Why?
| | Anti-Arrhythmia Agents | 4 | 2014 | 144 | 0.620 |
Why?
| | Back Pain | 1 | 2020 | 52 | 0.620 |
Why?
| | Hospitals, Pediatric | 4 | 2018 | 557 | 0.610 |
Why?
| | Suicide, Attempted | 5 | 2012 | 422 | 0.610 |
Why?
| | Vasoconstrictor Agents | 4 | 2009 | 150 | 0.610 |
Why?
| | Free Radical Scavengers | 2 | 2011 | 82 | 0.610 |
Why?
| | Buprenorphine | 2 | 2020 | 190 | 0.590 |
Why?
| | Patient Handoff | 1 | 2020 | 44 | 0.590 |
Why?
| | Haloperidol | 1 | 2019 | 32 | 0.580 |
Why?
| | Ketorolac | 1 | 2019 | 32 | 0.580 |
Why?
| | Retrospective Studies | 31 | 2023 | 17247 | 0.580 |
Why?
| | Emergency Medical Services | 5 | 2025 | 684 | 0.570 |
Why?
| | Social Work | 1 | 2020 | 85 | 0.570 |
Why?
| | Pharmacoepidemiology | 1 | 2018 | 22 | 0.570 |
Why?
| | Gastric Lavage | 3 | 2009 | 9 | 0.550 |
Why?
| | Immunoglobulin Fab Fragments | 4 | 2019 | 56 | 0.550 |
Why?
| | Colorado | 15 | 2021 | 4538 | 0.540 |
Why?
| | Vomiting | 6 | 2019 | 131 | 0.540 |
Why?
| | Tertiary Care Centers | 3 | 2017 | 195 | 0.540 |
Why?
| | Hypotension | 2 | 2022 | 127 | 0.530 |
Why?
| | Prospective Studies | 18 | 2023 | 8035 | 0.520 |
Why?
| | Drug Storage | 2 | 2017 | 53 | 0.520 |
Why?
| | Substance-Related Disorders | 5 | 2012 | 1093 | 0.520 |
Why?
| | Child | 28 | 2023 | 22670 | 0.510 |
Why?
| | Accidents, Home | 1 | 2017 | 33 | 0.510 |
Why?
| | Medical Marijuana | 2 | 2019 | 122 | 0.500 |
Why?
| | Cannabinoids | 3 | 2017 | 184 | 0.500 |
Why?
| | Fibrin Fibrinogen Degradation Products | 2 | 2007 | 92 | 0.500 |
Why?
| | Plant Preparations | 2 | 2015 | 37 | 0.500 |
Why?
| | Pulmonary Embolism | 3 | 2021 | 241 | 0.490 |
Why?
| | Calcium Gluconate | 1 | 2016 | 4 | 0.490 |
Why?
| | Electronic Health Records | 4 | 2024 | 1188 | 0.490 |
Why?
| | Quaternary Ammonium Compounds | 1 | 2016 | 50 | 0.480 |
Why?
| | Hypocalcemia | 1 | 2016 | 39 | 0.470 |
Why?
| | Health Records, Personal | 1 | 2016 | 26 | 0.470 |
Why?
| | Nonprescription Drugs | 4 | 2016 | 69 | 0.470 |
Why?
| | Blood Proteins | 1 | 2017 | 238 | 0.460 |
Why?
| | Mobile Applications | 1 | 2018 | 199 | 0.460 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 5 | 2023 | 261 | 0.460 |
Why?
| | Fat Emulsions, Intravenous | 2 | 2014 | 29 | 0.450 |
Why?
| | Antidepressive Agents | 2 | 2012 | 239 | 0.450 |
Why?
| | Practice Patterns, Physicians' | 3 | 2023 | 1365 | 0.440 |
Why?
| | Prescription Drug Misuse | 1 | 2015 | 52 | 0.440 |
Why?
| | Liver | 6 | 2022 | 1893 | 0.440 |
Why?
| | Electrocardiography | 5 | 2013 | 664 | 0.430 |
Why?
| | Infant | 13 | 2023 | 10060 | 0.420 |
Why?
| | Treatment Outcome | 18 | 2020 | 11741 | 0.420 |
Why?
| | Asymptomatic Diseases | 2 | 2013 | 103 | 0.410 |
Why?
| | Child, Preschool | 13 | 2018 | 11835 | 0.410 |
Why?
| | Crime | 2 | 2011 | 57 | 0.400 |
Why?
| | Observer Variation | 3 | 2010 | 356 | 0.400 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 1 | 2013 | 25 | 0.400 |
Why?
| | Energy Drinks | 1 | 2013 | 3 | 0.400 |
Why?
| | Performance-Enhancing Substances | 1 | 2013 | 11 | 0.390 |
Why?
| | Poisons | 2 | 2023 | 20 | 0.380 |
Why?
| | Diet Surveys | 1 | 2013 | 90 | 0.380 |
Why?
| | Plasmapheresis | 1 | 2013 | 24 | 0.380 |
Why?
| | Arrhythmias, Cardiac | 3 | 2022 | 355 | 0.380 |
Why?
| | Accidents | 1 | 2013 | 46 | 0.380 |
Why?
| | Bradycardia | 1 | 2013 | 61 | 0.380 |
Why?
| | Amphotericin B | 1 | 2013 | 36 | 0.380 |
Why?
| | Hematemesis | 1 | 2012 | 4 | 0.380 |
Why?
| | Phytotherapy | 1 | 2013 | 74 | 0.380 |
Why?
| | Adolescent | 27 | 2020 | 22479 | 0.380 |
Why?
| | Double-Blind Method | 7 | 2020 | 2057 | 0.380 |
Why?
| | Aspartate Aminotransferases | 3 | 2010 | 85 | 0.380 |
Why?
| | Stomach Diseases | 1 | 2012 | 20 | 0.380 |
Why?
| | Foreign Bodies | 2 | 2011 | 110 | 0.370 |
Why?
| | Ethers | 1 | 2012 | 19 | 0.370 |
Why?
| | beta-Alanine | 1 | 2012 | 25 | 0.370 |
Why?
| | Sulfonylurea Compounds | 2 | 2010 | 51 | 0.370 |
Why?
| | Citalopram | 1 | 2012 | 32 | 0.360 |
Why?
| | Liver Function Tests | 7 | 2020 | 105 | 0.360 |
Why?
| | Drug Administration Schedule | 5 | 2014 | 781 | 0.360 |
Why?
| | Antithrombins | 1 | 2012 | 71 | 0.360 |
Why?
| | Propafenone | 1 | 2011 | 2 | 0.360 |
Why?
| | Antifungal Agents | 1 | 2013 | 150 | 0.350 |
Why?
| | Thiophenes | 1 | 2012 | 117 | 0.350 |
Why?
| | Genetic Predisposition to Disease | 1 | 2020 | 2351 | 0.350 |
Why?
| | Anaphylaxis | 2 | 2012 | 102 | 0.350 |
Why?
| | Firesetting Behavior | 1 | 2011 | 1 | 0.350 |
Why?
| | C-Peptide | 2 | 2010 | 190 | 0.350 |
Why?
| | Clinical Enzyme Tests | 2 | 2013 | 9 | 0.340 |
Why?
| | Charcoal | 4 | 2006 | 27 | 0.340 |
Why?
| | Infusions, Intravenous | 6 | 2013 | 428 | 0.340 |
Why?
| | Disease Models, Animal | 9 | 2011 | 4552 | 0.340 |
Why?
| | Dronabinol | 4 | 2021 | 249 | 0.340 |
Why?
| | Benzimidazoles | 1 | 2012 | 189 | 0.340 |
Why?
| | Temperance | 2 | 2010 | 20 | 0.340 |
Why?
| | Aged | 27 | 2019 | 26096 | 0.340 |
Why?
| | Alcohol Drinking | 4 | 2012 | 836 | 0.340 |
Why?
| | Chemical and Drug Induced Liver Injury, Chronic | 1 | 2011 | 11 | 0.330 |
Why?
| | Administration, Intravenous | 4 | 2016 | 171 | 0.330 |
Why?
| | Evidence-Based Medicine | 4 | 2023 | 739 | 0.330 |
Why?
| | Cholinergic Antagonists | 1 | 2011 | 24 | 0.330 |
Why?
| | Brain Edema | 1 | 2011 | 62 | 0.330 |
Why?
| | Amitriptyline | 2 | 2001 | 24 | 0.330 |
Why?
| | Opioid-Related Disorders | 2 | 2020 | 600 | 0.330 |
Why?
| | Blood Chemical Analysis | 3 | 2021 | 109 | 0.320 |
Why?
| | Reproducibility of Results | 6 | 2024 | 3410 | 0.320 |
Why?
| | Tachycardia, Ventricular | 1 | 2012 | 180 | 0.320 |
Why?
| | Self-Injurious Behavior | 1 | 2012 | 141 | 0.320 |
Why?
| | Immunologic Factors | 2 | 2019 | 260 | 0.320 |
Why?
| | Liver Failure | 1 | 2011 | 83 | 0.320 |
Why?
| | Hydrofluoric Acid | 2 | 2016 | 7 | 0.320 |
Why?
| | Aged, 80 and over | 15 | 2018 | 8318 | 0.310 |
Why?
| | Pharmaceutical Vehicles | 1 | 2010 | 12 | 0.310 |
Why?
| | Propylene Glycol | 1 | 2010 | 9 | 0.310 |
Why?
| | Burns | 2 | 2015 | 374 | 0.310 |
Why?
| | Population Surveillance | 1 | 2013 | 484 | 0.310 |
Why?
| | Barium | 1 | 2009 | 27 | 0.310 |
Why?
| | Explosive Agents | 1 | 2009 | 8 | 0.310 |
Why?
| | Time Factors | 12 | 2020 | 7107 | 0.310 |
Why?
| | Imines | 2 | 2022 | 6 | 0.300 |
Why?
| | Hypokalemia | 1 | 2009 | 24 | 0.300 |
Why?
| | Acidosis, Lactic | 1 | 2010 | 46 | 0.300 |
Why?
| | Liver Diseases, Alcoholic | 2 | 2007 | 98 | 0.300 |
Why?
| | Emetics | 2 | 2006 | 7 | 0.300 |
Why?
| | United States | 18 | 2025 | 16065 | 0.300 |
Why?
| | Deception | 1 | 2009 | 18 | 0.300 |
Why?
| | Liver Failure, Acute | 2 | 2023 | 68 | 0.290 |
Why?
| | Random Allocation | 3 | 2007 | 365 | 0.290 |
Why?
| | Warfarin | 1 | 2010 | 179 | 0.290 |
Why?
| | Benzoquinones | 2 | 2022 | 46 | 0.290 |
Why?
| | Iatrogenic Disease | 1 | 2010 | 74 | 0.290 |
Why?
| | Cross-Sectional Studies | 9 | 2020 | 5886 | 0.290 |
Why?
| | Surveys and Questionnaires | 4 | 2018 | 6055 | 0.280 |
Why?
| | Odds Ratio | 7 | 2017 | 1082 | 0.280 |
Why?
| | Fluorides | 2 | 2016 | 49 | 0.280 |
Why?
| | Risk Factors | 9 | 2017 | 10857 | 0.280 |
Why?
| | Oximetry | 1 | 2009 | 125 | 0.280 |
Why?
| | Risk Assessment | 8 | 2017 | 3740 | 0.280 |
Why?
| | Hypothermia, Induced | 1 | 2009 | 95 | 0.280 |
Why?
| | Length of Stay | 3 | 2020 | 1348 | 0.270 |
Why?
| | Cyanoacrylates | 1 | 2008 | 3 | 0.270 |
Why?
| | Eyelashes | 1 | 2008 | 4 | 0.270 |
Why?
| | Adhesives | 1 | 2008 | 15 | 0.270 |
Why?
| | Reference Values | 4 | 2017 | 798 | 0.270 |
Why?
| | Detergents | 1 | 2008 | 43 | 0.270 |
Why?
| | Point-of-Care Systems | 1 | 2010 | 188 | 0.270 |
Why?
| | Intellectual Disability | 1 | 2009 | 178 | 0.270 |
Why?
| | Publishing | 1 | 2009 | 114 | 0.270 |
Why?
| | Cardiovascular System | 1 | 2009 | 138 | 0.260 |
Why?
| | Hypoglycemia | 2 | 2010 | 479 | 0.260 |
Why?
| | Alcoholism | 4 | 2023 | 819 | 0.260 |
Why?
| | Animals | 22 | 2019 | 37952 | 0.260 |
Why?
| | Polyethylene Glycols | 1 | 2012 | 649 | 0.260 |
Why?
| | Brugada Syndrome | 1 | 2007 | 14 | 0.260 |
Why?
| | Niacin | 1 | 2007 | 16 | 0.260 |
Why?
| | Diazepam | 1 | 2007 | 33 | 0.260 |
Why?
| | Clinical Laboratory Techniques | 1 | 2008 | 96 | 0.260 |
Why?
| | Mice, Inbred Strains | 4 | 2009 | 396 | 0.250 |
Why?
| | Vitamin B Complex | 1 | 2007 | 39 | 0.250 |
Why?
| | Brain Infarction | 1 | 2006 | 23 | 0.240 |
Why?
| | Thromboembolism | 1 | 2007 | 129 | 0.240 |
Why?
| | Pediatrics | 1 | 2015 | 1121 | 0.240 |
Why?
| | Specimen Handling | 1 | 2008 | 182 | 0.240 |
Why?
| | Pyrazoles | 2 | 2023 | 517 | 0.240 |
Why?
| | Analgesics | 4 | 2017 | 230 | 0.230 |
Why?
| | Decontamination | 1 | 2006 | 28 | 0.230 |
Why?
| | Nausea | 4 | 2014 | 112 | 0.230 |
Why?
| | Amiodarone | 1 | 2005 | 31 | 0.230 |
Why?
| | Hypoxia-Ischemia, Brain | 1 | 2006 | 49 | 0.230 |
Why?
| | Self Report | 4 | 2021 | 867 | 0.230 |
Why?
| | Age Factors | 7 | 2017 | 3338 | 0.230 |
Why?
| | Eating | 4 | 2017 | 387 | 0.230 |
Why?
| | Intention | 1 | 2007 | 186 | 0.230 |
Why?
| | Vasospasm, Intracranial | 1 | 2005 | 19 | 0.220 |
Why?
| | Venous Thrombosis | 1 | 2007 | 195 | 0.220 |
Why?
| | Sodium Nitrite | 1 | 2005 | 39 | 0.220 |
Why?
| | Anticoagulants | 1 | 2010 | 748 | 0.220 |
Why?
| | Drug Utilization | 5 | 2014 | 167 | 0.220 |
Why?
| | Calcium | 3 | 2016 | 1189 | 0.220 |
Why?
| | Epilepsy | 2 | 2020 | 390 | 0.220 |
Why?
| | Subarachnoid Hemorrhage | 1 | 2005 | 71 | 0.220 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2012 | 1742 | 0.220 |
Why?
| | Diagnostic Imaging | 1 | 2007 | 337 | 0.210 |
Why?
| | Education, Medical | 2 | 2021 | 274 | 0.210 |
Why?
| | Coma | 2 | 2006 | 38 | 0.210 |
Why?
| | Databases, Factual | 1 | 2010 | 1488 | 0.210 |
Why?
| | Acute Kidney Injury | 1 | 2012 | 872 | 0.210 |
Why?
| | Biomarkers | 7 | 2021 | 4282 | 0.210 |
Why?
| | Hospitals, Urban | 5 | 2021 | 142 | 0.200 |
Why?
| | Injections, Intraperitoneal | 4 | 2009 | 115 | 0.200 |
Why?
| | Animal Experimentation | 1 | 2003 | 8 | 0.200 |
Why?
| | Anti-Anxiety Agents | 2 | 2020 | 48 | 0.200 |
Why?
| | Triage | 2 | 2025 | 250 | 0.200 |
Why?
| | Case-Control Studies | 4 | 2022 | 3616 | 0.200 |
Why?
| | Calcium Chloride | 1 | 2003 | 10 | 0.190 |
Why?
| | Sensitivity and Specificity | 5 | 2010 | 1995 | 0.190 |
Why?
| | Glasgow Coma Scale | 1 | 2004 | 218 | 0.190 |
Why?
| | Insulin | 3 | 2019 | 2510 | 0.190 |
Why?
| | Hypoglycemic Agents | 2 | 2010 | 1393 | 0.190 |
Why?
| | Hospitals, Teaching | 3 | 2014 | 120 | 0.190 |
Why?
| | Magnesium Sulfate | 1 | 2003 | 18 | 0.190 |
Why?
| | Fibrinolytic Agents | 2 | 2021 | 297 | 0.190 |
Why?
| | Placebos | 2 | 2014 | 193 | 0.180 |
Why?
| | Umbilical Cord | 2 | 2021 | 92 | 0.180 |
Why?
| | Documentation | 1 | 2024 | 199 | 0.180 |
Why?
| | Desipramine | 1 | 2001 | 10 | 0.180 |
Why?
| | Longevity | 3 | 2009 | 177 | 0.180 |
Why?
| | Logistic Models | 3 | 2017 | 2133 | 0.180 |
Why?
| | Phenylurea Compounds | 1 | 2022 | 119 | 0.170 |
Why?
| | Confidence Intervals | 4 | 2010 | 330 | 0.170 |
Why?
| | Cardiopulmonary Resuscitation | 3 | 2018 | 336 | 0.170 |
Why?
| | Substance Withdrawal Syndrome | 1 | 2023 | 185 | 0.170 |
Why?
| | Research Design | 3 | 2006 | 1132 | 0.170 |
Why?
| | Severity of Illness Index | 1 | 2009 | 2928 | 0.170 |
Why?
| | Hyperthermia, Induced | 1 | 2022 | 120 | 0.170 |
Why?
| | Sinus Thrombosis, Intracranial | 1 | 2021 | 25 | 0.170 |
Why?
| | Narcotic Antagonists | 2 | 2020 | 202 | 0.160 |
Why?
| | Heart Atria | 1 | 2001 | 141 | 0.160 |
Why?
| | Fractures, Bone | 2 | 2017 | 426 | 0.160 |
Why?
| | Opiate Substitution Treatment | 2 | 2020 | 186 | 0.160 |
Why?
| | Acute Disease | 2 | 2019 | 1035 | 0.160 |
Why?
| | Myocardial Contraction | 1 | 2001 | 291 | 0.160 |
Why?
| | Immunoglobulin Fragments | 1 | 1999 | 11 | 0.150 |
Why?
| | Droperidol | 1 | 1999 | 4 | 0.150 |
Why?
| | Wisconsin | 1 | 2020 | 99 | 0.150 |
Why?
| | Lithium Carbonate | 1 | 1999 | 6 | 0.150 |
Why?
| | Lysergic Acid Diethylamide | 1 | 1999 | 4 | 0.150 |
Why?
| | Serotonin Syndrome | 1 | 1999 | 4 | 0.150 |
Why?
| | Starch | 1 | 2019 | 22 | 0.150 |
Why?
| | Scorpion Stings | 1 | 1999 | 1 | 0.150 |
Why?
| | Serotonin Receptor Agonists | 1 | 1999 | 27 | 0.150 |
Why?
| | Survival Analysis | 4 | 2010 | 1371 | 0.150 |
Why?
| | Nutritive Value | 1 | 2019 | 41 | 0.150 |
Why?
| | Healthy Volunteers | 2 | 2019 | 219 | 0.150 |
Why?
| | Ventricular Premature Complexes | 1 | 1999 | 37 | 0.150 |
Why?
| | Thrombocytopenia | 1 | 2021 | 204 | 0.150 |
Why?
| | Immune System | 1 | 2020 | 177 | 0.150 |
Why?
| | Snake Bites | 1 | 1999 | 24 | 0.150 |
Why?
| | Geriatric Assessment | 2 | 2011 | 238 | 0.150 |
Why?
| | Administration, Oral | 4 | 2019 | 862 | 0.140 |
Why?
| | Pregnancy, Tubal | 1 | 1998 | 5 | 0.140 |
Why?
| | Fallopian Tube Diseases | 1 | 1998 | 6 | 0.140 |
Why?
| | Dietary Carbohydrates | 1 | 2019 | 147 | 0.140 |
Why?
| | Munchausen Syndrome by Proxy | 1 | 1998 | 2 | 0.140 |
Why?
| | Abortifacient Agents, Nonsteroidal | 1 | 1998 | 20 | 0.140 |
Why?
| | Metabolome | 1 | 2022 | 387 | 0.140 |
Why?
| | Community Health Workers | 1 | 2020 | 88 | 0.140 |
Why?
| | Plant Extracts | 1 | 2020 | 188 | 0.140 |
Why?
| | Drug Therapy, Combination | 4 | 2011 | 1043 | 0.140 |
Why?
| | Chi-Square Distribution | 2 | 2017 | 527 | 0.140 |
Why?
| | Cohort Studies | 7 | 2023 | 5988 | 0.140 |
Why?
| | Mass Screening | 1 | 2007 | 1354 | 0.140 |
Why?
| | Sex Factors | 5 | 2022 | 2099 | 0.140 |
Why?
| | Sulfasalazine | 1 | 1998 | 22 | 0.130 |
Why?
| | Drug Antagonism | 2 | 2009 | 10 | 0.130 |
Why?
| | Cannabidiol | 1 | 2020 | 142 | 0.130 |
Why?
| | Anticonvulsants | 1 | 2020 | 246 | 0.130 |
Why?
| | Genome-Wide Association Study | 2 | 2023 | 1376 | 0.130 |
Why?
| | Drug Interactions | 4 | 2014 | 404 | 0.130 |
Why?
| | Faculty, Medical | 1 | 2021 | 301 | 0.130 |
Why?
| | Dyspnea | 1 | 1999 | 250 | 0.130 |
Why?
| | Dietary Fats | 1 | 2019 | 308 | 0.130 |
Why?
| | Peptide Fragments | 1 | 2021 | 693 | 0.130 |
Why?
| | Methotrexate | 1 | 1998 | 233 | 0.130 |
Why?
| | Gastrointestinal Agents | 1 | 1998 | 65 | 0.130 |
Why?
| | Continuity of Patient Care | 1 | 2020 | 296 | 0.130 |
Why?
| | Out-of-Hospital Cardiac Arrest | 1 | 2018 | 121 | 0.130 |
Why?
| | Incidence | 4 | 2013 | 2915 | 0.120 |
Why?
| | Survival Rate | 3 | 2013 | 2087 | 0.120 |
Why?
| | Fellowships and Scholarships | 1 | 2021 | 354 | 0.120 |
Why?
| | Ammonium Compounds | 1 | 2016 | 2 | 0.120 |
Why?
| | Mice | 8 | 2009 | 18303 | 0.120 |
Why?
| | Energy Intake | 1 | 2019 | 507 | 0.120 |
Why?
| | Cytochrome P-450 CYP2E1 Inhibitors | 1 | 2016 | 2 | 0.120 |
Why?
| | Simulation Training | 1 | 2018 | 135 | 0.120 |
Why?
| | Prenatal Care | 1 | 2019 | 309 | 0.120 |
Why?
| | Metabolic Clearance Rate | 2 | 2019 | 115 | 0.120 |
Why?
| | Ventricular Fibrillation | 1 | 2016 | 64 | 0.120 |
Why?
| | Half-Life | 2 | 2019 | 153 | 0.120 |
Why?
| | Hypnotics and Sedatives | 1 | 1998 | 222 | 0.120 |
Why?
| | Clinical Trials as Topic | 2 | 2012 | 1058 | 0.120 |
Why?
| | Pharmacovigilance | 1 | 2015 | 24 | 0.120 |
Why?
| | Pain Management | 2 | 2017 | 409 | 0.120 |
Why?
| | Milk | 1 | 2016 | 119 | 0.120 |
Why?
| | Predictive Value of Tests | 3 | 2015 | 2115 | 0.110 |
Why?
| | Genetic Variation | 1 | 2020 | 967 | 0.110 |
Why?
| | Fatal Outcome | 2 | 2013 | 305 | 0.110 |
Why?
| | Herniorrhaphy | 1 | 2016 | 76 | 0.110 |
Why?
| | Adverse Drug Reaction Reporting Systems | 1 | 2015 | 81 | 0.110 |
Why?
| | Hemodialysis Units, Hospital | 1 | 1994 | 5 | 0.110 |
Why?
| | Models, Biological | 2 | 2015 | 1763 | 0.110 |
Why?
| | Child Behavior | 1 | 2017 | 236 | 0.110 |
Why?
| | Ondansetron | 1 | 2014 | 19 | 0.110 |
Why?
| | Pilot Projects | 1 | 2020 | 1889 | 0.110 |
Why?
| | Total Quality Management | 1 | 1994 | 57 | 0.110 |
Why?
| | Cytochrome P-450 CYP2D6 | 1 | 2014 | 32 | 0.110 |
Why?
| | Hydrocodone | 1 | 2014 | 18 | 0.110 |
Why?
| | Patient Simulation | 1 | 2014 | 42 | 0.100 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2015 | 98 | 0.100 |
Why?
| | Transaminases | 1 | 2014 | 22 | 0.100 |
Why?
| | Oxycodone | 1 | 2014 | 52 | 0.100 |
Why?
| | Guanfacine | 1 | 2013 | 5 | 0.100 |
Why?
| | Clonidine | 1 | 2013 | 33 | 0.100 |
Why?
| | Physicians | 2 | 2020 | 954 | 0.100 |
Why?
| | Food | 1 | 2015 | 150 | 0.100 |
Why?
| | Curriculum | 1 | 2021 | 1067 | 0.100 |
Why?
| | International Normalized Ratio | 2 | 2011 | 55 | 0.100 |
Why?
| | Vitamins | 1 | 2015 | 182 | 0.100 |
Why?
| | Cesium | 1 | 2013 | 20 | 0.100 |
Why?
| | Indazoles | 1 | 2014 | 83 | 0.100 |
Why?
| | Internship and Residency | 2 | 2014 | 1264 | 0.100 |
Why?
| | Acute Pain | 1 | 2014 | 58 | 0.100 |
Why?
| | Remote Consultation | 1 | 2014 | 66 | 0.100 |
Why?
| | Prognosis | 3 | 2011 | 4310 | 0.100 |
Why?
| | Deoxycholic Acid | 1 | 2013 | 14 | 0.100 |
Why?
| | Lethargy | 1 | 2012 | 4 | 0.090 |
Why?
| | Pregnancy Complications | 1 | 2019 | 600 | 0.090 |
Why?
| | Duloxetine Hydrochloride | 1 | 2012 | 10 | 0.090 |
Why?
| | Walking | 1 | 2017 | 542 | 0.090 |
Why?
| | Pain Measurement | 4 | 2019 | 554 | 0.090 |
Why?
| | Canada | 2 | 2025 | 429 | 0.090 |
Why?
| | Dabigatran | 1 | 2012 | 30 | 0.090 |
Why?
| | Tachycardia | 1 | 2012 | 57 | 0.090 |
Why?
| | Chlorides | 1 | 2013 | 138 | 0.090 |
Why?
| | Sleep Stages | 1 | 2012 | 76 | 0.090 |
Why?
| | Sulfhydryl Reagents | 1 | 2012 | 12 | 0.090 |
Why?
| | Data Collection | 2 | 2013 | 639 | 0.090 |
Why?
| | Marijuana Abuse | 1 | 2015 | 211 | 0.090 |
Why?
| | Attitude of Health Personnel | 1 | 2020 | 1186 | 0.090 |
Why?
| | Mycoses | 1 | 2013 | 88 | 0.090 |
Why?
| | Sampling Studies | 1 | 2012 | 98 | 0.090 |
Why?
| | Arsenicals | 1 | 2012 | 28 | 0.090 |
Why?
| | Magnesium | 2 | 2004 | 156 | 0.090 |
Why?
| | Athletic Performance | 1 | 2013 | 78 | 0.090 |
Why?
| | Dizziness | 1 | 2012 | 101 | 0.090 |
Why?
| | Information Systems | 1 | 2011 | 56 | 0.090 |
Why?
| | Patient Discharge | 2 | 2016 | 991 | 0.090 |
Why?
| | Drug Combinations | 1 | 2013 | 396 | 0.090 |
Why?
| | Marijuana Smoking | 1 | 2015 | 249 | 0.080 |
Why?
| | Immunocompromised Host | 1 | 2013 | 202 | 0.080 |
Why?
| | Sulfides | 1 | 2012 | 92 | 0.080 |
Why?
| | Arabia | 1 | 2011 | 2 | 0.080 |
Why?
| | Levamisole | 1 | 2011 | 21 | 0.080 |
Why?
| | Accidental Falls | 2 | 2011 | 225 | 0.080 |
Why?
| | Hepatic Encephalopathy | 1 | 2011 | 25 | 0.080 |
Why?
| | Follow-Up Studies | 3 | 2010 | 5411 | 0.080 |
Why?
| | Structure-Activity Relationship | 1 | 2012 | 563 | 0.080 |
Why?
| | Laparoscopy | 1 | 2016 | 481 | 0.080 |
Why?
| | Drug Contamination | 1 | 2011 | 53 | 0.080 |
Why?
| | Molecular Structure | 1 | 2012 | 486 | 0.080 |
Why?
| | Dietary Supplements | 1 | 2015 | 582 | 0.080 |
Why?
| | Universities | 1 | 2013 | 443 | 0.080 |
Why?
| | Sports | 1 | 2013 | 211 | 0.080 |
Why?
| | Pharmacogenetics | 1 | 2012 | 174 | 0.080 |
Why?
| | Glipizide | 1 | 2010 | 6 | 0.080 |
Why?
| | Laboratories, Hospital | 1 | 2010 | 14 | 0.080 |
Why?
| | Hepatitis, Alcoholic | 1 | 2010 | 16 | 0.080 |
Why?
| | Troponin | 1 | 2010 | 50 | 0.080 |
Why?
| | Glyburide | 1 | 2010 | 31 | 0.080 |
Why?
| | Crowding | 1 | 2010 | 37 | 0.080 |
Why?
| | Body Weight | 1 | 2014 | 969 | 0.080 |
Why?
| | Biological Availability | 2 | 2019 | 144 | 0.080 |
Why?
| | Drug Prescriptions | 2 | 2016 | 287 | 0.080 |
Why?
| | Adjuvants, Immunologic | 1 | 2011 | 243 | 0.070 |
Why?
| | Quetiapine Fumarate | 1 | 2009 | 26 | 0.070 |
Why?
| | Dibenzothiazepines | 1 | 2009 | 18 | 0.070 |
Why?
| | Watchful Waiting | 1 | 2010 | 90 | 0.070 |
Why?
| | Aripiprazole | 1 | 2009 | 20 | 0.070 |
Why?
| | Risperidone | 1 | 2009 | 30 | 0.070 |
Why?
| | Role | 1 | 2009 | 28 | 0.070 |
Why?
| | Potassium | 1 | 2009 | 152 | 0.070 |
Why?
| | Head Protective Devices | 1 | 2009 | 24 | 0.070 |
Why?
| | Efficiency, Organizational | 1 | 2010 | 141 | 0.070 |
Why?
| | Quality Control | 1 | 2009 | 161 | 0.070 |
Why?
| | Dogs | 1 | 2010 | 438 | 0.070 |
Why?
| | Acidosis | 2 | 2006 | 105 | 0.070 |
Why?
| | Glutathione | 3 | 2022 | 370 | 0.070 |
Why?
| | Bibliometrics | 1 | 2009 | 66 | 0.070 |
Why?
| | Verapamil | 2 | 2014 | 37 | 0.070 |
Why?
| | Renal Dialysis | 1 | 2013 | 466 | 0.070 |
Why?
| | Diarrhea | 1 | 2009 | 193 | 0.070 |
Why?
| | Body Temperature | 1 | 2009 | 227 | 0.070 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2011 | 288 | 0.070 |
Why?
| | Quality Indicators, Health Care | 1 | 2011 | 336 | 0.070 |
Why?
| | Skiing | 1 | 2009 | 49 | 0.070 |
Why?
| | Workload | 1 | 2010 | 168 | 0.070 |
Why?
| | Bacitracin | 1 | 2008 | 5 | 0.070 |
Why?
| | Adhesiveness | 1 | 2008 | 18 | 0.070 |
Why?
| | Hair Preparations | 1 | 2008 | 3 | 0.070 |
Why?
| | Acetone | 1 | 2008 | 12 | 0.070 |
Why?
| | Pharmacy Service, Hospital | 1 | 2009 | 89 | 0.070 |
Why?
| | Propylene Glycols | 1 | 2008 | 28 | 0.070 |
Why?
| | Equipment Design | 1 | 2009 | 525 | 0.070 |
Why?
| | Nylons | 1 | 2008 | 24 | 0.070 |
Why?
| | Informed Consent | 2 | 2006 | 198 | 0.070 |
Why?
| | Withholding Treatment | 1 | 2008 | 80 | 0.070 |
Why?
| | Cellulose | 1 | 2008 | 58 | 0.070 |
Why?
| | Cause of Death | 1 | 2010 | 470 | 0.070 |
Why?
| | Glycerol | 1 | 2008 | 90 | 0.070 |
Why?
| | Students | 1 | 2013 | 650 | 0.060 |
Why?
| | Drug Synergism | 1 | 2008 | 354 | 0.060 |
Why?
| | Nephelometry and Turbidimetry | 1 | 2007 | 15 | 0.060 |
Why?
| | Laboratories | 1 | 2008 | 110 | 0.060 |
Why?
| | Health Services Accessibility | 1 | 2015 | 1099 | 0.060 |
Why?
| | Substance Abuse Detection | 2 | 2021 | 106 | 0.060 |
Why?
| | Tissue Distribution | 2 | 2019 | 335 | 0.060 |
Why?
| | Polypharmacy | 1 | 2008 | 94 | 0.060 |
Why?
| | Phosphates | 1 | 2008 | 177 | 0.060 |
Why?
| | Research | 2 | 2011 | 430 | 0.060 |
Why?
| | Formates | 1 | 2006 | 15 | 0.060 |
Why?
| | Quinolones | 1 | 2009 | 203 | 0.060 |
Why?
| | Defibrillators | 1 | 2006 | 23 | 0.060 |
Why?
| | Combined Modality Therapy | 1 | 2009 | 1264 | 0.060 |
Why?
| | Periodicals as Topic | 1 | 2009 | 209 | 0.060 |
Why?
| | Military Personnel | 1 | 2014 | 736 | 0.060 |
Why?
| | Methanol | 1 | 2006 | 44 | 0.060 |
Why?
| | Statistics, Nonparametric | 1 | 2007 | 427 | 0.060 |
Why?
| | Vasopressins | 1 | 2006 | 61 | 0.060 |
Why?
| | Kidney Transplantation | 1 | 2013 | 710 | 0.060 |
Why?
| | Blindness | 1 | 2006 | 51 | 0.060 |
Why?
| | Probability | 2 | 2010 | 307 | 0.060 |
Why?
| | Spinal Diseases | 1 | 2006 | 50 | 0.060 |
Why?
| | Health Services for the Aged | 1 | 2006 | 72 | 0.060 |
Why?
| | Respiratory Insufficiency | 1 | 2009 | 326 | 0.060 |
Why?
| | Ipecac | 1 | 2005 | 8 | 0.060 |
Why?
| | Naproxen | 1 | 2006 | 21 | 0.060 |
Why?
| | Epinephrine | 1 | 2006 | 158 | 0.060 |
Why?
| | Population Dynamics | 1 | 2006 | 142 | 0.060 |
Why?
| | Hospitalization | 2 | 2011 | 2458 | 0.060 |
Why?
| | Hospitals, University | 1 | 2006 | 176 | 0.060 |
Why?
| | Aging | 2 | 2014 | 1962 | 0.060 |
Why?
| | Haplorhini | 1 | 2005 | 52 | 0.060 |
Why?
| | Ibuprofen | 1 | 2006 | 86 | 0.060 |
Why?
| | Premedication | 1 | 2005 | 45 | 0.060 |
Why?
| | Geriatrics | 1 | 2006 | 95 | 0.050 |
Why?
| | Practice Guidelines as Topic | 2 | 2014 | 1579 | 0.050 |
Why?
| | Telemedicine | 1 | 2014 | 956 | 0.050 |
Why?
| | Risk | 1 | 2007 | 916 | 0.050 |
Why?
| | Spine | 1 | 2006 | 181 | 0.050 |
Why?
| | Respiration, Artificial | 1 | 2009 | 713 | 0.050 |
Why?
| | Water | 1 | 2008 | 445 | 0.050 |
Why?
| | Single-Blind Method | 1 | 2005 | 316 | 0.050 |
Why?
| | Motivation | 1 | 2009 | 600 | 0.050 |
Why?
| | Fluoride Poisoning | 1 | 2004 | 3 | 0.050 |
Why?
| | Phenobarbital | 1 | 2023 | 21 | 0.050 |
Why?
| | Blood Glucose | 2 | 2019 | 2335 | 0.050 |
Why?
| | Guidelines as Topic | 1 | 2005 | 266 | 0.050 |
Why?
| | Hydroxyzine | 1 | 2023 | 3 | 0.050 |
Why?
| | Maltose | 1 | 2023 | 8 | 0.050 |
Why?
| | Resuscitation | 1 | 2006 | 310 | 0.050 |
Why?
| | Health Policy | 1 | 2006 | 400 | 0.050 |
Why?
| | Mycophenolic Acid | 1 | 2004 | 120 | 0.050 |
Why?
| | Delphi Technique | 1 | 2025 | 330 | 0.050 |
Why?
| | Sheep | 1 | 2006 | 876 | 0.050 |
Why?
| | Survival | 1 | 2003 | 38 | 0.050 |
Why?
| | Urea | 1 | 2023 | 85 | 0.050 |
Why?
| | Consensus | 1 | 2025 | 478 | 0.050 |
Why?
| | Patient Participation | 1 | 2006 | 437 | 0.050 |
Why?
| | Aspirin | 1 | 2006 | 406 | 0.050 |
Why?
| | Pregnancy | 3 | 2021 | 7182 | 0.050 |
Why?
| | Lactates | 1 | 2022 | 82 | 0.050 |
Why?
| | Internet | 1 | 2007 | 689 | 0.040 |
Why?
| | Sex Distribution | 2 | 2015 | 386 | 0.040 |
Why?
| | Culture Techniques | 1 | 2001 | 66 | 0.040 |
Why?
| | Urban Population | 2 | 2019 | 492 | 0.040 |
Why?
| | Blood Physiological Phenomena | 1 | 2021 | 12 | 0.040 |
Why?
| | Prevalence | 3 | 2015 | 2855 | 0.040 |
Why?
| | Neural Conduction | 1 | 2001 | 92 | 0.040 |
Why?
| | Hirudins | 1 | 2021 | 53 | 0.040 |
Why?
| | Academic Medical Centers | 2 | 2016 | 552 | 0.040 |
Why?
| | Calcium Channel Blockers | 1 | 2001 | 166 | 0.040 |
Why?
| | Breast Neoplasms | 1 | 2013 | 2380 | 0.040 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2020 | 27 | 0.040 |
Why?
| | Infusions, Parenteral | 1 | 2020 | 48 | 0.040 |
Why?
| | Pirenzepine | 1 | 1999 | 8 | 0.040 |
Why?
| | Scorpions | 1 | 1999 | 3 | 0.040 |
Why?
| | South America | 1 | 1999 | 56 | 0.040 |
Why?
| | Blood Cell Count | 2 | 2013 | 55 | 0.040 |
Why?
| | Temperature | 1 | 2022 | 632 | 0.040 |
Why?
| | Certification | 1 | 2020 | 119 | 0.040 |
Why?
| | Narcotics | 1 | 1999 | 58 | 0.040 |
Why?
| | Rupture, Spontaneous | 1 | 1998 | 15 | 0.040 |
Why?
| | Immunosuppressive Agents | 1 | 2004 | 837 | 0.040 |
Why?
| | Central Nervous System Depressants | 1 | 1999 | 84 | 0.040 |
Why?
| | Analysis of Variance | 1 | 2001 | 1300 | 0.040 |
Why?
| | Postprandial Period | 1 | 2019 | 114 | 0.040 |
Why?
| | Videotape Recording | 1 | 2018 | 37 | 0.040 |
Why?
| | Manikins | 1 | 2018 | 36 | 0.040 |
Why?
| | Sorption Detoxification | 1 | 1998 | 2 | 0.040 |
Why?
| | Ambulatory Care | 1 | 2023 | 608 | 0.030 |
Why?
| | Dietary Proteins | 1 | 2019 | 135 | 0.030 |
Why?
| | North America | 1 | 1999 | 301 | 0.030 |
Why?
| | Cholinesterase Inhibitors | 1 | 1998 | 47 | 0.030 |
Why?
| | Laparotomy | 1 | 1998 | 113 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2021 | 1368 | 0.030 |
Why?
| | Feedback | 1 | 2018 | 180 | 0.030 |
Why?
| | Cardiomyopathies | 1 | 2001 | 335 | 0.030 |
Why?
| | Triglycerides | 1 | 2019 | 520 | 0.030 |
Why?
| | Maternal Health Services | 1 | 2019 | 101 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2001 | 887 | 0.030 |
Why?
| | Lipids | 1 | 2022 | 706 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 2019 | 608 | 0.030 |
Why?
| | Central Nervous System | 1 | 1999 | 281 | 0.030 |
Why?
| | Socioeconomic Factors | 2 | 2015 | 1321 | 0.030 |
Why?
| | Bipolar Disorder | 1 | 1999 | 275 | 0.030 |
Why?
| | Registries | 2 | 2010 | 2401 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2019 | 1066 | 0.030 |
Why?
| | Dialysis | 1 | 2015 | 19 | 0.030 |
Why?
| | Hallucinogens | 1 | 2017 | 111 | 0.030 |
Why?
| | Centrifugation | 1 | 2015 | 28 | 0.030 |
Why?
| | Tennessee | 1 | 1994 | 57 | 0.030 |
Why?
| | Observation | 1 | 2014 | 54 | 0.030 |
Why?
| | Hematocrit | 1 | 1994 | 108 | 0.030 |
Why?
| | Program Evaluation | 1 | 2018 | 943 | 0.030 |
Why?
| | Syndrome | 1 | 2015 | 380 | 0.030 |
Why?
| | International Classification of Diseases | 1 | 2015 | 149 | 0.030 |
Why?
| | Anesthetics, Local | 1 | 2014 | 104 | 0.030 |
Why?
| | Warfare | 1 | 2014 | 98 | 0.030 |
Why?
| | Erythropoietin | 1 | 1994 | 100 | 0.020 |
Why?
| | Protein Binding | 1 | 2020 | 2235 | 0.020 |
Why?
| | Injections, Intralesional | 1 | 2013 | 35 | 0.020 |
Why?
| | Hospitals, Veterans | 1 | 1994 | 258 | 0.020 |
Why?
| | Salicylates | 1 | 2013 | 29 | 0.020 |
Why?
| | Urinalysis | 1 | 2013 | 83 | 0.020 |
Why?
| | Nursing Staff, Hospital | 1 | 1994 | 143 | 0.020 |
Why?
| | Long QT Syndrome | 1 | 2013 | 68 | 0.020 |
Why?
| | Hemoglobins | 1 | 1994 | 386 | 0.020 |
Why?
| | Therapeutic Irrigation | 1 | 2012 | 68 | 0.020 |
Why?
| | Iron | 1 | 1994 | 357 | 0.020 |
Why?
| | Receptors, Opioid, mu | 1 | 2012 | 66 | 0.020 |
Why?
| | Agranulocytosis | 1 | 2011 | 30 | 0.020 |
Why?
| | Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2011 | 8 | 0.020 |
Why?
| | False Negative Reactions | 1 | 2011 | 61 | 0.020 |
Why?
| | Computer Simulation | 1 | 2015 | 1002 | 0.020 |
Why?
| | Leukoencephalopathies | 1 | 2011 | 24 | 0.020 |
Why?
| | Models, Theoretical | 1 | 1994 | 556 | 0.020 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2012 | 161 | 0.020 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2011 | 124 | 0.020 |
Why?
| | Insulin Resistance | 1 | 2019 | 1244 | 0.020 |
Why?
| | Toothache | 1 | 2010 | 5 | 0.020 |
Why?
| | Fluid Therapy | 1 | 2012 | 154 | 0.020 |
Why?
| | Immunoassay | 1 | 2011 | 109 | 0.020 |
Why?
| | Quality of Health Care | 1 | 2015 | 692 | 0.020 |
Why?
| | Disease Outbreaks | 1 | 2014 | 419 | 0.020 |
Why?
| | Drug Administration Routes | 1 | 2010 | 42 | 0.020 |
Why?
| | Insurance Coverage | 1 | 2012 | 244 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2010 | 197 | 0.020 |
Why?
| | Neurologic Examination | 1 | 2010 | 132 | 0.020 |
Why?
| | Patient Education as Topic | 1 | 1994 | 775 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2012 | 614 | 0.020 |
Why?
| | Age Distribution | 1 | 2010 | 402 | 0.020 |
Why?
| | Intestines | 1 | 2012 | 354 | 0.020 |
Why?
| | Kidney Failure, Chronic | 1 | 1994 | 599 | 0.020 |
Why?
| | Safety | 1 | 2010 | 357 | 0.020 |
Why?
| | Regression Analysis | 1 | 2010 | 998 | 0.020 |
Why?
| | Precision Medicine | 1 | 2012 | 459 | 0.020 |
Why?
| | Ethanol | 1 | 2012 | 631 | 0.020 |
Why?
| | Seasons | 1 | 2010 | 538 | 0.020 |
Why?
| | Disease Management | 1 | 2011 | 651 | 0.020 |
Why?
| | Bilirubin | 1 | 2007 | 99 | 0.020 |
Why?
| | Pulse | 1 | 2006 | 29 | 0.020 |
Why?
| | Genotype | 1 | 2012 | 1844 | 0.020 |
Why?
| | Blastomycosis | 1 | 2006 | 11 | 0.020 |
Why?
| | Contraindications | 1 | 2006 | 90 | 0.020 |
Why?
| | Clinical Competence | 1 | 2014 | 1240 | 0.010 |
Why?
| | Biopsy, Fine-Needle | 1 | 2006 | 68 | 0.010 |
Why?
| | Amyloidosis | 1 | 2006 | 44 | 0.010 |
Why?
| | Metabolomics | 1 | 2012 | 730 | 0.010 |
Why?
| | Coronary Circulation | 1 | 2006 | 134 | 0.010 |
Why?
| | European Union | 1 | 2005 | 12 | 0.010 |
Why?
| | Electric Countershock | 1 | 2006 | 126 | 0.010 |
Why?
| | Fever | 1 | 2007 | 318 | 0.010 |
Why?
| | Disaster Planning | 1 | 2006 | 101 | 0.010 |
Why?
| | Emergencies | 1 | 2006 | 174 | 0.010 |
Why?
| | Administration, Inhalation | 1 | 2006 | 571 | 0.010 |
Why?
| | Infant, Newborn | 2 | 2007 | 6435 | 0.010 |
Why?
| | United States Food and Drug Administration | 1 | 2005 | 207 | 0.010 |
Why?
| | Pharmaceutical Preparations | 1 | 2006 | 170 | 0.010 |
Why?
| | Up-Regulation | 1 | 2007 | 846 | 0.010 |
Why?
| | Renal Insufficiency | 1 | 2006 | 172 | 0.010 |
Why?
| | Swine | 1 | 2006 | 822 | 0.010 |
Why?
| | Mice, Inbred ICR | 1 | 2004 | 113 | 0.010 |
Why?
| | Brain Injuries | 1 | 2009 | 507 | 0.010 |
Why?
| | Phenotype | 1 | 2012 | 3138 | 0.010 |
Why?
| | Lupus Nephritis | 1 | 2004 | 67 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2004 | 1048 | 0.010 |
Why?
| | Papillary Muscles | 1 | 2001 | 13 | 0.010 |
Why?
| | Models, Cardiovascular | 1 | 2001 | 195 | 0.010 |
Why?
| | Miosis | 1 | 1999 | 4 | 0.010 |
Why?
| | Blood Pressure | 1 | 2006 | 1778 | 0.010 |
Why?
| | Pupil | 1 | 1999 | 22 | 0.010 |
Why?
| | Hemodynamics | 1 | 2004 | 1115 | 0.010 |
Why?
| | Chronic Disease | 1 | 2004 | 1806 | 0.010 |
Why?
| | Algorithms | 1 | 2004 | 1845 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2001 | 2524 | 0.010 |
Why?
| | Rats | 1 | 2001 | 5582 | 0.010 |
Why?
| | Neoplasms | 1 | 2006 | 2900 | 0.010 |
Why?
|
|
Heard's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|